{"filings":[{"id":92755,"accession_number":"0001193125-26-204006","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Rein Therapeutics prices $50M public offering of 50M shares at $1.00/share","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Gross proceeds $50M from 50M shares at $1.00; net proceeds ~$46.1M after discounts and expenses.","Underwriter granted 45-day option for up to 7.5M additional shares; warrants for 3% of sold shares at $1.50.","Bios entities defer conversion of 12,232 Series X preferred shares and lock-up through April 2029; receive 3M warrants at $1.00.","Proceeds to fully fund Phase 2 trial of LTI-03 in IPF; cash runway extended into 2028.","Konik Capital Partners (T.R. Winston) acts as sole book-running manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103859,"accession_number":"0001193125-26-084012","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Rein Therapeutics issues $2.875M in unsecured notes to institutional investors at 20% OID","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2.875M aggregate principal notes for $2.3M net cash (20% original issue discount).","Notes mature 30 days after $10M+ equity raise or by June 30, 2026; no cash interest.","Private placement to three institutional investors; notes are unsecured general obligations.","Proceeds for working capital; sold under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103858,"accession_number":"0001193125-26-059545","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Manuel C. Alves Aivado resigns from Rein Therapeutics board effective Feb 16","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Manuel C. Alves Aivado, M.D., Ph.D., resigned as board member effective February 16, 2026.","Resignation was not the result of any disagreement with the company's operations, policies, or practices.","No replacement has been announced; board size and composition subsequent to departure not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103857,"accession_number":"0001193125-26-015524","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Rein Therapeutics issues $2.5M unsecured promissory note with 20% OID to Funicular Funds","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2.5M principal unsecured promissory note sold for $2M (20% original issue discount) to Funicular Funds, LP.","Note matures on earlier of next $10M+ equity closing or June 30, 2026; no periodic interest.","Proceeds from private placement provide working capital; note exempt under Section 4(a)(2) and Rule 506.","Agreement includes customary representations, warranties, and covenants; note is unsecured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120128,"accession_number":"0001193125-25-316225","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Rein Therapeutics terminates Yorkville equity facility; $3M drawn, no penalties","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Pre-Paid Advance and Standby Equity Purchase Agreements with Yorkville on Dec 11, 2025.","Total $3M in advances drawn under PPA; most recent advance on Oct 23, 2025.","No sales of common stock executed under the Standby Equity Purchase Agreement.","No penalties or fees incurred in connection with the termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120127,"accession_number":"0001193125-25-261706","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Rein Therapeutics' Phase 2 trial of LTI-03 for IPF","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA lifted full clinical hold after Rein's Complete Response submission; agency confirmed all concerns resolved.","Company expects to resume U.S. patient enrollment in late 2025 or early 2026 across ~20 clinical sites.","Global Phase 2 RENEW trial to enroll up to 120 IPF patients; topline data expected in Q3 2026.","LTI-03 aims to slow fibrosis and promote lung repair, per CEO Brian Windsor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120126,"accession_number":"0001193125-25-250175","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Rein Therapeutics receives third $1.0M Pre-Paid Advance from Yorkville at 95% discount","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third Pre-Paid Advance of $1.0M on Oct 23, 2025; net proceeds $0.95M; total potential up to $6.0M.","Interest accrues at 8% annually (18% on default); advances due 12 months from issuance.","Yorkville may demand common stock issuance to offset outstanding balance; prior advances converted at avg prices ~$1.0562 and ~$1.0825 per share.","First and Second Advances of $1.0M each previously drawn; combined shares issued: ~1.88M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120125,"accession_number":"0001193125-25-235152","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rein Therapeutics receives EMA authorization to begin Phase 2 trial of LTI-03 for IPF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["European Medicines Agency approved Phase 2 RENEW trial at clinical sites in Germany and Poland.","Global randomized, double-blind, placebo-controlled study will enroll up to 120 IPF patients over 24 weeks.","LTI-03 is a Caveolin-1-derived peptide designed to inhibit fibrosis and support lung tissue regeneration.","Company previously received UK MHRA clearance; trial will evaluate safety, tolerability, and efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136704,"accession_number":"0001193125-25-210050","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA agrees MCH/H findings not dose-limiting for Rein Therapeutics' LTI-03 Phase 2 trial; CRL submission planned","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed MCH/H findings in GLP rat studies are not dose-limiting for proposed 24-week LTI-03 protocol at doses up to 10 mg/day in IPF patients.","FDA stated Complete Response Letter (CRL) need not include new GLP rat toxicity study; Rein will prepare CRL in coming weeks.","FDA recommended CRL include updated clinical safety, PK/PD data, augmented safety monitoring with spirometry, and DSMB unblinded reviews.","Clinical hold on U.S. Phase 2 RENEW trial (LTI-03) remains; company hopeful for timely release after CRL submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136703,"accession_number":"0001193125-25-198816","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Rein Therapeutics secures up to $6.0M in prepaid advances from Yorkville; second $1.0M tranche drawn","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered Pre-Paid Advance Agreement with Yorkville for up to $6.0M over 12 months; initial $1.0M advance closed July 29, 2025.","As of Sept 8, 2025, 479,036 shares issued at avg $1.06 to Yorkville, offsetting $500K of initial advance.","Second $1.0M advance drawn on Sept 8, 2025 ($0.95M net proceeds); Yorkville may demand stock to reduce balance.","Advances have 8% interest (18% default), 12-month maturity; each advance sold at 95% of face amount."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136702,"accession_number":"0001193125-25-183073","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).","Trial will enroll up to 120 patients globally; two dose groups vs placebo over 24 weeks.","Primary endpoint: safety/tolerability; secondary: lung function and imaging-based fibrosis measures.","Patient recruitment in UK to begin soon; initial data expected in 2026.","LTI-03 is first-in-class, designed to target fibrosis and protect lung regeneration; IPF median survival is 3-5 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136701,"accession_number":"0001193125-25-168830","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.","Standby Equity Purchase Agreement: up to $15M over 36 months; shares sold at 96% of lowest 3-day VWAP.","Floor price set at $0.28 per share; Yorkville may require share issuance at lower of 115% of VWAP or 95% of lowest 7-day VWAP.","Commitment fee of $300k paid as 213,099 shares plus $25k structuring fees; Exchange Cap limited to 19.9% of outstanding shares.","Proceeds used for general corporate purposes; shares registered on Form S-3 (File No. 333-287342)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136700,"accession_number":"0001193125-25-163400","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Rein Therapeutics stockholders elect director Fairey, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["William C. Fairey elected as Class II director for three-year term expiring 2028; 7,661,847 for, 1,621,599 withheld.","Advisory vote on named executive officer compensation approved: 8,325,803 for, 146,938 against, 810,705 abstain.","Meeting held July 23, 2025, after being adjourned from June 24, 2025; no broker non-votes recorded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136699,"accession_number":"0001193125-25-158192","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Rein Therapeutics receives FDA clinical hold on LTI-03 Phase 2 trial; cites insufficient nonclinical safety data","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed Phase 2 RENEW trial of LTI-03 on clinical hold on July 8, 2025 via formal letter.","FDA cited no NOAEL and minimal mucus cell hyperplasia in 26-week rat study; requests new inhalation toxicity study.","Company believes existing data supports safety, plans to work with FDA to resolve hold expeditiously.","Board approved bylaw amendment lowering quorum requirement to 40% of shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153918,"accession_number":"0001193125-25-145711","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rein Therapeutics adjourns annual meeting to July 23 due to lack of quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting originally set for June 24, 2025, adjourned after quorum not achieved.","Meeting rescheduled to Wednesday, July 23, 2025, to allow more stockholder voting.","Record date remains May 5, 2025; proposals unchanged from proxy filed May 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153917,"accession_number":"0001193125-25-139950","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Rein Therapeutics pauses US enrollment in Phase 2 RENEW trial due to FDA clinical hold","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on Phase 2 RENEW trial of LTI-03 on June 10, 2025; US enrollment and dosing paused.","Rein is working with FDA to address non-clinical requests to resume US enrollment.","Trial continues with site initiation and patient enrollment in Australia, UK, and Europe.","No drug-related serious adverse events reported across all LTI-03 studies.","LTI-03 is a novel Caveolin-1-related peptide for idiopathic pulmonary fibrosis (IPF)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153916,"accession_number":"0001193125-25-120824","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.","Cash $7.4M at Mar 31, plus $5.28M from April warrant/private placement; runway to Sep 2025.","Phase 2 RENEW trial of LTI-03 in IPF initiated; topline interim data expected H1 2026.","Two U.S. patents granted for LTI-03 dry powder formulation (Apr 22, 2025).","R&D expense $3.1M, G&A $2.5M, both down vs prior year on lower legal and LTI-01 costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153915,"accession_number":"0001193125-25-087955","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Rein Therapeutics raises ~$5.05M via warrant exercises, exchanges, and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercise 2023 and 2024 warrants for 902,929 shares at reduced price of $1.60 per share.","Holders of 2023 warrants exchange 1,939,000 shares for pre-funded warrants plus cash payment of ~$1.599/share.","Bios affiliate purchases pre-funded warrants for 312,695 shares at $1.599 per share in private placement.","Total gross proceeds expected to be approximately $5.05 million.","Pre-funded warrants are immediately exercisable at $0.001 per share, subject to beneficial ownership limit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153914,"accession_number":"0001193125-25-084340","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Rein Therapeutics auditor Marcum resigns, CBIZ appointed; going concern noted","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Marcum LLP resigned as independent auditor on April 16, 2025; CBIZ CPAs P.C. engaged by Audit Committee.","Marcum's reports for 2024 and 2023 included a going concern explanatory paragraph for Rein Therapeutics.","No disagreements on accounting principles or practices between Marcum and the company.","Material weaknesses in internal controls over financial reporting were reported for both 2024 and 2023.","Company authorized Marcum to fully respond to successor auditor inquiries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172568,"accession_number":"0001193125-25-004443","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Rein Therapeutics (formerly Aileron) changes name to Rein Therapeutics, new ticker RNTX","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from Aileron Therapeutics to Rein Therapeutics effective January 10, 2025 at 4:00 p.m. Eastern Time.","New trading symbol RNTX on Nasdaq Capital Market; trading under new name and symbol starts January 13, 2025.","CUSIP number for common stock remains unchanged; no impact on stockholder rights.","Certificate of amendment and amended bylaws filed as exhibits to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189563,"accession_number":"0001193125-24-258568","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.","Cash and equivalents at $17.7M as of Sept 30, 2024, expected to fund operations into June 2025.","Phase 1b high-dose LTI-03 (5mg BID) in IPF showed dose-dependent biomarker effects; combined cohort data achieved statistical significance in 4 of 8 biomarkers.","Planning underway for Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF).","Exclusive option agreement with Advancium Health Network for ALRN-6924 (oncology) granted; non-refundable fee received, potential milestone and royalty payments."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206066,"accession_number":"0001193125-24-204425","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Aileron Therapeutics 2024 annual meeting: re-elects directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Brian Windsor, Ph.D. and Alan A. Musso as Class I directors (7.8M for, ~24k withheld each, 3.4M broker non-votes).","Advisory vote on named executive officer compensation passed: 7.3M for, 109k against, 416k abstain.","Ratified Marcum LLP as independent auditor for FY 2024: 10.8M for, 61k against, 416k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206065,"accession_number":"0001193125-24-200739","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.","Cash $21.9M as of June 30, 2024; raised $18.2M net from May 2024 registered direct offering.","Cohort 1 of Phase 1b LTI-03 (2.5 mg BID) showed positive trends in 7 of 8 biomarkers with statistical significance in 3 fibrosis-related biomarkers.","LTI-03 was generally well-tolerated; topline results from high-dose Cohort 2 expected in Q3 2024.","Company expects cash to fund operations into second half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206064,"accession_number":"0001193125-24-186279","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aileron Therapeutics enters into ATM equity distribution agreement for up to $50M with Citizens JMP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Equity Distribution Agreement with Citizens JMP Securities for at-the-market sales of common stock up to $50M.","Terminated prior Capital on Demand agreement with JonesTrading and William Blair effective July 26, 2024.","Agent commission set at 3.0% of gross proceeds from share sales.","Shares sold under existing shelf registration statement; no specific amount required to be sold.","Offering conducted on Nasdaq Capital Market; either party may suspend or terminate upon notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223095,"accession_number":"0001193125-24-154675","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Aileron sets 2024 annual meeting for Aug 20; shareholder proposals due June 15","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting date changed to August 20, 2024, more than 30 days from last year's anniversary.","Deadline for Rule 14a-8 stockholder proposals is June 15, 2024.","Deadline for director nominations under bylaws is also June 15, 2024.","Proposals must comply with bylaws and SEC rules to be considered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223094,"accession_number":"0001193125-24-140688","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.","Cunningham is a consultant from Danforth Advisors, providing CFO services at an hourly rate under consulting agreement.","Cunningham, age 62, CPA, has served as CFO for Bionomics Limited and other biotech firms; no family relationships with executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223093,"accession_number":"0001193125-24-139510","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.","Cash $12.0M at March 31, 2024; after May 2024 $20M offering, expects to fund operations into H2 2025.","Positive Cohort 1 data for LTI-03 in IPF: statistically significant in 3 of 8 biomarkers; no SAEs reported.","Topline results from high-dose Cohort 2 expected Q3 2024; also Brian Windsor appointed President and CEO in March."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223092,"accession_number":"0001193125-24-127657","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.","Warrants exercisable at $4.68/share for 3 years; callable by Aileron after top-line LTI-03 Phase 1b results if VWAP exceeds exercise price.","Net proceeds to fund LTI-03 Phase 1b trial, working capital; cash runway projected through Q2 2025.","Offering closing on May 3, 2024; Titan Partners Group acted as sole book-runner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223091,"accession_number":"0001193125-24-126425","cik":1420565,"company_name":"Rein Therapeutics, Inc.","ticker":"RNTX","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).","LTI-03 well-tolerated with no serious adverse events; solRAGE increased (p=0.1407), indicating type I epithelial cell health.","Cohort 1: 12 patients (9 active, 3 placebo), inhaled 2.5 mg BID; cohort 2 high-dose results expected Q3 2024.","Preliminary cash and cash equivalents ~$12.0M as of March 31, 2024, unaudited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":91954454.41037734,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}